TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06693011: Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)

Sponsor: Cerus Endovascular, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 250 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$4,448,800

Rescue Site Savings

+$2,921,600

Unlock Full NCT06693011 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06693011 Rescue Dossier →